Dermatologicals in China

PROSPECTS

Increasing prevalence of hair loss and awareness of self-medication continue to propel hair loss treatment

Hair loss treatments continued to prosper in 2019, as hair loss becomes increasingly prevalent and the trend towards self-medication grows. Hair loss has become increasingly common amongst Chinese consumers, with almost 1 in 5 males estimated to encounter such problems.

Nappy (diaper) rash treatments witnesses healthy growth due to increasing usage and trade-up trend

Nappy (diaper) rash treatments continues to grow as usage increases and the average unit price of products purchased also rises. Nappy (diaper) rash is quite common amongst babies using nappies, and usually nappy rash is mild and can be treated by parents using the appropriate treatment.

Western medicine more popular than traditional products

A feature of dermatologicals is that consumers want rapid treatment for many dermatological problems. Therefore, in comparison with medicines with herbal/traditional constituents, Western medicine is more popular amongst Chinese consumers.

COMPETITIVE LANDSCAPE

Xian Janssen Pharmaceutical Co Ltd enhances its leading position in dermatologicals

Xian Janssen Pharmaceutical Co Ltd retained the lead in dermatologicals in 2019, with its well-known brands, Daktarin and Pevisone. In 2019, both brands witnessed growth, and helped Xian Janssen Pharmaceutical Co Ltd to remain the largest player in overall dermatologicals, despite continued share erosion.

Bayer adjusts strategy to strengthen medicated shampoo offer

Dihon Pharmaceutical Group Co (GBO Bayer) has adjusted its strategy and launched a new product for one of its star brands, Kang Wang, in order to maintain Kang Wang’s presence in medicated shampoo. The single-formula ketoconazole medicated shampoo was launched in 2018, after the compound ketoconazole medicated shampoo was switched to Rx in the middle of 2017.

Files are delivered directly into your account within a few minutes of purchase.